PA8474101A1
(es)
*
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
AU3951899A
(en)
|
1998-06-19 |
2000-01-05 |
Pfizer Products Inc. |
Pyrrolo(2,3-d)pyrimidine compounds
|
EP1510212A1
(de)
*
|
1998-08-21 |
2005-03-02 |
Parker Hughes Institute |
Verwendung von 4-substituerte Chinazolin-Derivaten zur Herstellung von therapeutischen Mitteln
|
MXPA01001893A
(es)
*
|
1998-08-21 |
2002-04-24 |
Parker Hughes Inst |
Derivados de quinazolina.
|
US6080747A
(en)
*
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
WO2001045641A2
(en)
*
|
1999-11-30 |
2001-06-28 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
AP1905A
(en)
*
|
1999-12-10 |
2008-10-20 |
Pfizer Prod Inc |
Pyrrolo[2,3-d] Pyrimidine Compounds.
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
UA74370C2
(uk)
*
|
2000-06-26 |
2005-12-15 |
Пфайзер Продактс Інк. |
Піроло(2,3-d)піримідинові сполуки як імуносупресори
|
DE60132466T2
(de)
*
|
2000-08-08 |
2008-12-24 |
Philadelphia Health And Education Corp. |
Verfahren zur Herstellung menschlicher Lungenmastzell-Kulturen
|
PL202812B1
(pl)
|
2000-08-21 |
2009-07-31 |
Astrazeneca Ab |
Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
|
US20040044204A1
(en)
*
|
2000-09-20 |
2004-03-04 |
Werner Mederski |
4-amino-quinazolines
|
BR0114020A
(pt)
*
|
2000-09-20 |
2003-07-22 |
Merck Patent Gmbh |
4-amino-quinazolinas
|
US20040034045A1
(en)
*
|
2000-11-29 |
2004-02-19 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
ATE325795T1
(de)
*
|
2001-03-23 |
2006-06-15 |
Bayer Corp |
Rho-kinase inhibitoren
|
JP4320705B2
(ja)
*
|
2001-03-23 |
2009-08-26 |
バイエル コーポレイション |
Rhoキナーゼ阻害剤
|
US7301023B2
(en)
*
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
EP1408980A4
(de)
*
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
Neue chinazoline und ihre verwendungszwecke
|
US7829566B2
(en)
*
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
ES2320980T3
(es)
*
|
2001-11-03 |
2009-06-01 |
Astrazeneca Ab |
Derivados de quinazolina como agentes antitumorales.
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
GT200200234A
(es)
*
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
US20040014755A1
(en)
*
|
2002-01-10 |
2004-01-22 |
Dhanapalan Nagarathnam |
Rho-kinase inhibitors
|
ATE381557T1
(de)
*
|
2002-01-23 |
2008-01-15 |
Bayer Pharmaceuticals Corp |
Rho-kinase inhibitoren
|
JP4469179B2
(ja)
*
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
TWI324597B
(en)
*
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE60335099D1
(de)
|
2002-05-06 |
2011-01-05 |
Vertex Pharma |
Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
|
EP2280003B1
(de)
*
|
2002-07-15 |
2014-04-02 |
Symphony Evolution, Inc. |
Verfahren zur Herstellung von Rezeptorkinase-Modulatoren
|
BR0313059B8
(pt)
*
|
2002-07-29 |
2021-07-27 |
Rigel Pharmaceuticals |
composto, e, composição farmacêutica
|
BR0316487A
(pt)
*
|
2002-11-26 |
2005-10-11 |
Pfizer Prod Inc |
Método todo de tratamento da rejeição de transplantes
|
PL376844A1
(pl)
*
|
2002-12-09 |
2006-01-09 |
The Board Of Regents Of The University Of Texas System |
Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
*
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
US8309562B2
(en)
*
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
NZ544472A
(en)
*
|
2003-07-03 |
2009-04-30 |
Myriad Genetics Inc |
Compounds and therapeutical use thereof
|
MXPA06001079A
(es)
*
|
2003-07-29 |
2006-04-11 |
Astrazeneca Ab |
Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina.
|
GB0317665D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
RS53109B
(en)
*
|
2003-07-30 |
2014-06-30 |
Rigel Pharmaceuticals Inc. |
2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
|
GB0321648D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2539022A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
SI1667991T1
(sl)
*
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
US8318752B2
(en)
*
|
2003-09-19 |
2012-11-27 |
Astrazeneca Ab |
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
|
US20070037837A1
(en)
*
|
2003-09-19 |
2007-02-15 |
Hennequin Laurent Francois A |
Quinazoline derivatives
|
US20070043010A1
(en)
*
|
2003-09-25 |
2007-02-22 |
Astrazeneca Uk Limited |
Quinazoline derivatives
|
SI2392564T1
(sl)
*
|
2003-09-26 |
2014-02-28 |
Exelixis, Inc. |
c-Met modulatorji in postopki uporabe
|
US20070123537A1
(en)
*
|
2003-10-06 |
2007-05-31 |
Gpc Biotech Ag |
Quinazoline derivatives for the treatment of herpesviral infections
|
GB0326459D0
(en)
*
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
KR101164541B1
(ko)
*
|
2004-01-12 |
2012-07-10 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
선택적 키나제 저해제
|
CA2562198C
(en)
|
2004-04-12 |
2017-05-30 |
Sanbio Inc. |
Cells exhibiting neuronal progenitor cell characteristics
|
AU2005237254B2
(en)
*
|
2004-05-03 |
2010-02-04 |
Novartis Ag |
Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
|
US7405037B2
(en)
*
|
2004-05-07 |
2008-07-29 |
Lonza Walkersville, Inc. |
Methods and tools for detecting collagen degradation
|
MXPA06014125A
(es)
*
|
2004-06-04 |
2007-01-31 |
Astrazeneca Ab |
Derivados de quinazolina en la forma de cinasas de tirosina de receptor erbb.
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
US8258145B2
(en)
*
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
BRPI0606318B8
(pt)
*
|
2005-01-19 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, composição, e, uso de um composto
|
EP1856095B1
(de)
*
|
2005-02-26 |
2011-08-24 |
AstraZeneca AB |
Chinazolinderivate als tyrosinkinaseinhibitoren
|
WO2006094230A2
(en)
*
|
2005-03-03 |
2006-09-08 |
The Burnham Institute For Medical Research |
Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
RU2007140903A
(ru)
*
|
2005-04-05 |
2009-05-20 |
Фармакопия, Инк. (Us) |
Производные пурина и имидазопиридина для иммуносупрессии
|
US7884109B2
(en)
*
|
2005-04-05 |
2011-02-08 |
Wyeth Llc |
Purine and imidazopyridine derivatives for immunosuppression
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
WO2006133426A2
(en)
*
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
JP2009508917A
(ja)
*
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
抗癌剤としてのキナゾリン誘導体
|
JP2009508918A
(ja)
*
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
CN101321739A
(zh)
*
|
2005-12-02 |
2008-12-10 |
阿斯利康(瑞典)有限公司 |
用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物
|
JP2009517450A
(ja)
*
|
2005-12-02 |
2009-04-30 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体
|
US8409565B2
(en)
*
|
2006-02-14 |
2013-04-02 |
Francesca Levi-Schaffer |
Therapeutic target and diagnostic marker for asthma and related conditions
|
US7989459B2
(en)
*
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
US20090281075A1
(en)
*
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
ES2622493T3
(es)
*
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
EP2012815A4
(de)
|
2006-04-14 |
2009-12-09 |
Massachusetts Inst Technology |
Identifikation und modulierung molekularer pfade zur vermittlung neuronaler plastizität
|
US7902187B2
(en)
*
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
US7915268B2
(en)
*
|
2006-10-04 |
2011-03-29 |
Wyeth Llc |
8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
|
WO2008043031A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Pharmacopeia, Inc. |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
EP1921070A1
(de)
*
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US20080119496A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Pharmacopeia Drug Discovery, Inc. |
7-Substituted Purine Derivatives for Immunosuppression
|
EP2118075A1
(de)
*
|
2007-02-06 |
2009-11-18 |
Boehringer Ingelheim International GmbH |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
RU2445098C2
(ru)
*
|
2007-07-11 |
2012-03-20 |
Пфайзер Инк. |
Фармацевтические композиции и способы лечения сухих кератитов
|
EA019709B1
(ru)
*
|
2008-02-07 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Спирогетероциклы и их применение в качестве лекарственных средств
|
EP2265607B1
(de)
*
|
2008-02-15 |
2016-12-14 |
Rigel Pharmaceuticals, Inc. |
Pyrimidin-2-aminverbindungen und ihre verwendung als inhibitoren von jak-kinasen
|
EA019973B1
(ru)
|
2008-04-16 |
2014-07-30 |
Портола Фармасьютиклз, Инк. |
ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
EA019183B1
(ru)
|
2008-05-13 |
2014-01-30 |
Астразенека Аб |
Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
|
WO2010015522A1
(de)
*
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
PT2384326E
(pt)
|
2008-08-20 |
2014-06-09 |
Zoetis Llc |
Compostos de pirrolo[2,3-d]pirimidina
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
CA2995880C
(en)
|
2009-01-16 |
2021-01-05 |
Exelixis, Inc. |
Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
WO2010093808A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
CN102395576A
(zh)
*
|
2009-02-27 |
2012-03-28 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
AU2010281404A1
(en)
*
|
2009-07-28 |
2012-02-09 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
US8633207B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
WO2012030944A2
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline compounds and methods of use thereof
|
US9102625B2
(en)
|
2010-11-01 |
2015-08-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as JAK kinase modulators
|
CA2856301C
(en)
|
2011-11-23 |
2020-10-06 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
WO2014018195A1
(en)
*
|
2012-06-21 |
2014-01-30 |
Monsanto Technology Llc |
Lysis buffer and methods for extraction of dna from plant material
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
EP2903970A4
(de)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
Substituierte pyrimidinylkinasehemmer
|
US20180107782A1
(en)
*
|
2014-01-20 |
2018-04-19 |
Stevan Hubbard |
Atomic model for janus kinase-2 (jak2) and uses thereof
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
JOP20190144A1
(ar)
|
2016-12-16 |
2019-06-16 |
Janssen Pharmaceutica Nv |
إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
|
EP4086256A1
(de)
|
2016-12-16 |
2022-11-09 |
Janssen Pharmaceutica NV |
Kleinmolekülige inhibitoren der jak-familie von kinasen
|
TW202016110A
(zh)
|
2018-06-15 |
2020-05-01 |
比利時商健生藥品公司 |
Jak激酶家族之小分子抑制劑
|
JP2022527972A
(ja)
|
2019-04-02 |
2022-06-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
前悪性病変を有する患者において癌を予測及び予防する方法
|
US20220202820A1
(en)
|
2019-04-16 |
2022-06-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|